United States Patent 11,564,922 (Upadacitinib): Scope of Claims, Claim Construction Drivers, and US Patent Landscape for Crohn’s Disease Remission Induction/Maintenance
Executive summary
US Patent 11,564,922 claims a specific adult Crohn’s disease treatment regimen with upadacitinib: oral induction at 45 mg once daily for 12 weeks, followed by 15 mg once daily maintenance after the last induction dose, with outcomes tied to clinical remission using CDAI at 12 weeks (induction) and 52 weeks (maintenance), limited to patients with moderately to severely active Crohn’s disease and (in dependent form) anti-TNF inadequate response or intolerance. The claim scope is tightly anchored to (1) disease state, (2) step timing and sequencing, (3) dose levels, (4) route and frequency, and (5) clinical outcome metrics.
What exactly does US Patent 11,564,922 claim for upadacitinib in Crohn’s disease?
Direct claim coverage in plain terms
The independent claim (Claim 1) covers a method of treating an adult with moderately to severely active Crohn’s disease to achieve clinical remission by administering upadacitinib in a two-phase dosing schedule:
- Induction phase: oral 45 mg once daily for 12 weeks
- Maintenance phase: after the last 45 mg induction dose, oral 15 mg once daily
- Outcome linkage: the method “achieves clinical remission” in the patient
Claim 2 and Claim 3 specify CDAI timing points
- Claim 2 adds that the method achieves induction of clinical remission per CDAI at 12 weeks after the initial 45 mg dose.
- Claim 3 adds that the method achieves maintenance of clinical remission per CDAI at 52 weeks after administration of the initial maintenance dose of 15 mg.
Claim 4 narrows the eligible patient subgroup
- Claim 4 limits the method to adults who, prior to the initial induction dose, had an inadequate response or intolerance to an anti-TNF agent.
Key scope drivers that will control infringement and design-around
- Fixed induction dose and duration: 45 mg once daily for 12 weeks.
- Fixed maintenance dose: 15 mg once daily.
- Sequencing requirement: maintenance starts after the last induction dose.
- Adult moderately to severely active Crohn’s disease: eligibility is not general Crohn’s.
- Outcome requirement tied to clinical remission:
- Claim 2 and 3 require CDAI-defined remission at defined timepoints.
- Anti-TNF failure limitation (dependent claim):
- Claim 4 is narrower; the broad independent claim can still read on other patient populations if “moderately to severely active” and the remission outcome are met.
How narrow is the 11,564,922 regimen compared with other upadacitinib Crohn’s dosing claims?
What the claim reads like from a freedom-to-operate lens
This patent is not a broad “upadacitinib for Crohn’s disease” method. It is a regimen-specific method that is highly dependent on the exact dosing and timing.
Likely narrowest elements (high design-around leverage)
- Changing dose level (induction or maintenance) is the cleanest avoidable axis.
- Changing duration of induction (not 12 weeks) also shifts outside the literal method steps.
- Changing the frequency (e.g., not once daily) is another avoidable axis.
- Changing the maintenance initiation timing away from “after the last induction dose” is avoidable if it can be implemented without still matching the claimed step sequence.
Likely “harder” to design around
- “Clinical remission” as an outcome is still required. Even if a generic company argues remission could be achieved at different timepoints, Claim 2 and 3 explicitly pin CDAI remission at specified times.
- If an accused regimen is close but not exact, disputes typically center on whether CDAI measurement and meeting the remission threshold can be shown for the accused method.
What is the practical “claim construction” risk: CDAI remission language in US Patent 11,564,922?
CDAI timing creates evidence and proof dependencies
- Claim 2: remission per CDAI at 12 weeks from the initial induction dose.
- Claim 3: remission per CDAI at 52 weeks after the initial maintenance dose.
Why that matters for litigation
A method-of-treatment case tends to require demonstrating that the accused regimen, when performed, is capable of or does achieve the claimed endpoints in the patient population treated. The CDAI timing requirement will drive:
- trial protocol alignment (if data is available),
- post-hoc subgroup analyses matching CDAI-defined remission thresholds,
- chart review and measurement timing alignment.
Does 11,564,922 cover both induction and maintenance, or only the overall regimen?
Both, by design
Claim 1 is a combined method with both phases. Even if a regimen uses the same induction dose for 12 weeks but uses a different maintenance schedule, it will not satisfy Claim 1 if it does not include the 15 mg once daily maintenance portion in the claimed sequence and with remission outcome.
Dependent claim dependency structure
- Claims 2 and 3 do not add new drug steps. They add endpoint timing requirements.
- Claim 4 adds a patient eligibility predicate (anti-TNF inadequate response or intolerance) “prior to receiving the initial induction dose.”
What patents likely sit around 11,564,922 in the upadacitinib Crohn’s disease estate?
Core adjacent categories in a typical IL-23/JAK inhibitor Crohn’s patent family
Without relying on inferred numbering, the patent landscape around a specific US method claim like 11,564,922 typically clusters into:
- Dosing regimens and treatment schedules
- Method-of-use with disease activity strata
- Patient population limitations (anti-TNF inadequate responders)
- Biomarker-anchored endpoints (often CDAI-based)
- Formulation patents (tablet, extended-release variants, polymorphs)
- Manufacturing process patents
- Companion claims for other indications (ulcerative colitis, rheumatoid arthritis, psoriatic arthritis)
For upadacitinib specifically, the US patent estate relevant to Crohn’s typically includes multiple method-of-use patents that differ by:
- dose levels (e.g., induction vs maintenance),
- induction duration,
- endpoints (remission, response, endoscopy measures),
- patient selection criteria (anti-TNF failure vs treatment-naïve biologic status).
Business implication
If 11,564,922 is one of the regimen endpoints, other family members may protect:
- the same drug but different timing or dose,
- the same regimen but different endpoint definitions,
- the same regimen but different patient subgroups.
How does US 11,564,922 compare with earlier or later upadacitinib Crohn’s patents in likely scope?
In-range vs out-of-range design space
- If a competitor uses 45 mg induction for 12 weeks but a maintenance dose other than 15 mg once daily, it is likely outside literal coverage of Claim 1.
- If a competitor uses 15 mg maintenance once daily but changes induction duration (not 12 weeks), it is likely outside literal coverage.
- If a competitor uses CDAI-defined remission but measures endpoints at different timepoints, dependent claims 2 and 3 may not be met.
Litigation posture expectation
Regimen patents like this tend to produce claim construction fights around:
- whether the dosing steps were followed exactly,
- how remission thresholds are defined and assessed,
- whether the patient population meets “moderately to severely active” and (for Claim 4) anti-TNF failure criteria.
How strong is the patent estate for upadacitinib Crohn’s disease around 11,564,922?
Strength metrics that map to this claim
For a single method patent, practical strength is driven by:
- Degree of dosing precision (high precision tends to reduce infringement breadth but improves validity against overbroad prior art).
- Endpoint specificity (CDAI remission at fixed timepoints supports a clear inventive focus).
- Patient selection predicate (anti-TNF failure in Claim 4 adds narrower coverage but can help secure novelty for a subgroup).
Enforcement reality
Because the claim is a method, enforcement often relies on:
- prescribing and administration data,
- clinical trial protocols (if the regimen is identical),
- evidence that a standard of care regimen maps exactly to the claimed steps.
What generic entry risks exist for Crohn’s around 11,564,922?
Generic risk depends on whether the regimen is the labeled or practiced dosing
- If an FDA-approved labeling for upadacitinib in Crohn’s disease uses exactly the induction/maintenance schedule claimed, the method-of-use infringement exposure increases for parties inducing physicians or providing the drug under that regimen.
- If labeling differs (dose, schedule, or sequencing), generic risk decreases for direct method-of-use infringement but can persist under claims covering “off-label” use in certain jurisdictions if evidence supports actual practice.
Paragraph IV note
Method-of-use patents are commonly listed in Orange Book for reference listed drug (RLD) strategies when claims are tied to approved use. Generic Paragraph IV challenges often target the listed claims, but litigation outcomes depend on claim construction and whether the generics’ proposed labeling practice avoids the claimed steps.
What is the Orange Book status of 11,564,922 and how does that affect Paragraph IV challenges?
Direct answer
No Orange Book listing status is provided in the prompt text. Without the patent-to-Orange-Book mapping (RLD, NDA, listing type, and claim eligibility), the Orange Book status cannot be stated from the supplied information.
Where does 11,564,922 fit in FDA exclusivity: patent term vs marketing exclusivity?
Method patent affects patent term, not exclusivity
This kind of regimen patent constrains generic and biosimilar competition primarily through:
- US patent expiration (utility patent term, plus any extensions),
- and whether claims are listed against the FDA-approved indication that matches the claimed method.
What can be concluded from the claim itself
The claim is directed to a specific clinical treatment sequence that aligns with pivotal clinical development dosing strategies, which typically correspond to approved regimens if the trial endpoints supported efficacy.
Which companies are likely competing in the same Crohn’s dosing space as 11,564,922?
Not determinable from the provided prompt
The supplied text does not identify the assignee, family members, or any litigation parties. Without that, company-by-company mapping cannot be produced while staying faithful to the claim-only input.
What patent litigation affects 11,564,922?
Not determinable from the provided prompt
The supplied text provides claim text only. Litigation dates, dockets, and settlement terms cannot be asserted without case records or an established litigation reference.
Timeline: how the dosing schedule maps to clinical endpoints under 11,564,922
Claim 1 dosing timeline
- Day 1 to Week 12: 45 mg once daily induction
- Starting after the last 45 mg induction dose: maintenance 15 mg once daily
Claim 2 CDAI endpoint
- CDAI remission at Week 12 after initial induction dosing
Claim 3 CDAI endpoint
- CDAI remission at 52 weeks after initial maintenance dose
- This is a fixed time measurement relative to when 15 mg maintenance begins.
Structured timeline table
| Phase |
Dose |
Frequency |
Duration |
Claim endpoint linkage |
| Induction |
45 mg |
Once daily (oral) |
12 weeks |
Claim 2: CDAI remission at 12 weeks after initial induction dose |
| Maintenance |
15 mg |
Once daily (oral) |
Ongoing (at least through 52 weeks per Claim 3 proof point) |
Claim 3: CDAI remission at 52 weeks after initial maintenance dose |
Scope chart: element-by-element comparison for infringement analysis
| Claim element |
Requirement in US 11,564,922 |
High sensitivity to design-around |
| Patient |
Adult; moderately to severely active Crohn’s disease |
Medium (depends on eligibility criteria and evidence) |
| Drug |
Upadacitinib |
Low (non-pivot drug design-around) |
| Route |
Oral |
Medium |
| Induction dose |
45 mg |
High |
| Induction duration |
12 weeks |
High |
| Frequency |
Once daily |
Medium-High |
| Maintenance dose |
15 mg |
High |
| Maintenance timing |
After last induction dose |
Medium-High |
| Outcome |
Achieves clinical remission |
High evidentiary dependence |
| CDAI timing (Claim 2) |
Remission per CDAI at 12 weeks |
High |
| CDAI timing (Claim 3) |
Remission per CDAI at 52 weeks after initial maintenance dose |
High |
| Anti-TNF predicate (Claim 4) |
Inadequate response or intolerance to anti-TNF prior to induction |
High for Claim 4 only |
Key Takeaways
- US Patent 11,564,922 is a regimen-specific method-of-use patent: 45 mg once daily for 12 weeks induction, followed by 15 mg once daily maintenance in adult moderately to severely active Crohn’s disease to achieve clinical remission.
- Dependent claims tie infringement evidence to CDAI-defined remission at 12 weeks (induction) and 52 weeks after starting maintenance.
- Claim 4 narrows to adults with anti-TNF inadequate response or intolerance before induction.
- The claim’s precision on dose, timing, and CDAI endpoints makes it less about generic “upadacitinib in Crohn’s” broadly and more about whether an accused regimen matches the claimed steps and achieves the claimed outcomes.
FAQs
1) What happens if a Crohn’s regimen uses 45 mg once daily but a shorter induction than 12 weeks?
It is likely outside Claim 1’s literal induction duration requirement, and it may also fail Claim 2’s CDAI remission timing at 12 weeks.
2) If maintenance is 15 mg once daily but started before the last induction dose is complete, does Claim 1 still read?
Claim 1 requires maintenance “after the last induction dose,” so earlier maintenance initiation likely avoids the claimed sequence.
3) Does Claim 4 require anti-TNF failure for Claim 1 infringement?
No. Claim 4 is dependent and adds an eligibility predicate only for that dependent claim. Claim 1 does not include the anti-TNF predicate in the provided text.
4) How do the CDAI timing points affect evidence in patent litigation?
They force alignment of remission measurement with the asserted timepoints: 12 weeks from initial induction dosing for Claim 2 and 52 weeks from initial maintenance dosing for Claim 3.
5) Would changing remission assessment criteria (not CDAI) avoid the patent?
If the accused method does not achieve remission “per Crohn’s Disease Activity Index (CDAI)” as required by Claims 2 and 3, those dependent claims may not be met; Claim 1 still requires “clinical remission,” but the provided text does not specify CDAI for Claim 1.
References
- Provided patent claim text in the prompt (US Drug Patent 11,564,922).
